Antibody-Drug Conjugate (ADC) - Pipeline Insights, 2015; New Report Launched

Antibody-Drug Conjugate (ADC)- Pipeline Insights, 2015 report provides the in-depth analysis of the pipeline assets across the Antibody-Drug Conjugate (ADC). The report provides insights on around 200+ products and 160+ different Companies, which are active in this field. The report also throws the light on  60+ different technologies used by the companies for ADCs development.

The main objective of this report is to track competitor’s pipeline molecules, related research activities, technologies, collaborations, funding and licensing activities.. The Antibody-Drug Conjugate (ADC) Report helps to identify emerging players with potentially strong product information and to create effective counter-strategies to gain competitive advantage.

Antibody-Drug Conjugate (ADC)-Pipeline Insights, 2015 Report covers the Antibody-Drug Conjugate (ADC) pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also highlights the discontinued and inactive projects in pipeline for Antibody-Drug Conjugate (ADC).

Scope

• The report provides an Antibody-Drug Conjugate (ADC) Landscape across the globe
• The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
• Coverage of the Antibody-Drug Conjugate (ADC) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Antibody-Drug Conjugate (ADC) and also provide company profiling
• Pipeline products coverage based on various stages of development from NDA filings to discovery
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy

• Complete Pipeline intelligence and complete understanding over therapeutics development for Antibody-Drug Conjugate (ADC)
• Track your competitors and develop strategic initiatives to support your drug development activities
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business
• Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
• Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned

For further information on this report, please visit- http://mrr.cm/owq

Find all Drug Discovery Reports at: http://www.marketresearchreports.com/drug-discovery